Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
15.83
-0.96 (-5.72%)
At close: Nov 15, 2024, 4:00 PM
16.00
+0.17 (1.07%)
After-hours: Nov 15, 2024, 7:59 PM EST
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 184 employees as of December 31, 2023. The number of employees increased by 77 or 71.96% compared to the previous year.
Employees
184
Change (1Y)
77
Growth (1Y)
71.96%
Revenue / Employee
$86,957
Profits / Employee
-$1,614,467
Market Cap
1.35B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Myriad Genetics | 2,700 |
STAAR Surgical Company | 1,057 |
MiMedx Group | 895 |
Schrödinger | 867 |
Day One Biopharmaceuticals | 155 |
Praxis Precision Medicines | 82 |
ARS Pharmaceuticals | 26 |
SNDX News
- 19 hours ago - US FDA approves Syndax's blood cancer drug - Reuters
- 20 hours ago - Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation - PRNewsWire
- 3 days ago - Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity - Seeking Alpha
- 4 days ago - Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib - PRNewsWire
- 10 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 11 days ago - Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 - PRNewsWire
- 11 days ago - Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting - PRNewsWire